S&P 500   3,383.92 (+1.51%)
DOW   27,962.16 (+0.99%)
QQQ   272.20 (+2.64%)
AAPL   449.76 (+2.80%)
MSFT   208.91 (+2.72%)
FB   260.71 (+1.79%)
GOOGL   1,505.20 (+1.67%)
AMZN   3,155.67 (+2.43%)
NVDA   454.73 (+4.78%)
CGC   17.40 (+2.65%)
BABA   255.74 (+2.95%)
TSLA   1,527.24 (+11.12%)
GE   6.63 (-1.49%)
MU   48.33 (+1.19%)
AMD   82.24 (+6.97%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.92 (-1.00%)
GILD   68.86 (+1.12%)
NFLX   479.79 (+2.75%)
DIS   131.35 (+0.66%)
BAC   26.56 (-1.34%)
BA   173.96 (-3.43%)
S&P 500   3,383.92 (+1.51%)
DOW   27,962.16 (+0.99%)
QQQ   272.20 (+2.64%)
AAPL   449.76 (+2.80%)
MSFT   208.91 (+2.72%)
FB   260.71 (+1.79%)
GOOGL   1,505.20 (+1.67%)
AMZN   3,155.67 (+2.43%)
NVDA   454.73 (+4.78%)
CGC   17.40 (+2.65%)
BABA   255.74 (+2.95%)
TSLA   1,527.24 (+11.12%)
GE   6.63 (-1.49%)
MU   48.33 (+1.19%)
AMD   82.24 (+6.97%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.92 (-1.00%)
GILD   68.86 (+1.12%)
NFLX   479.79 (+2.75%)
DIS   131.35 (+0.66%)
BAC   26.56 (-1.34%)
BA   173.96 (-3.43%)
S&P 500   3,383.92 (+1.51%)
DOW   27,962.16 (+0.99%)
QQQ   272.20 (+2.64%)
AAPL   449.76 (+2.80%)
MSFT   208.91 (+2.72%)
FB   260.71 (+1.79%)
GOOGL   1,505.20 (+1.67%)
AMZN   3,155.67 (+2.43%)
NVDA   454.73 (+4.78%)
CGC   17.40 (+2.65%)
BABA   255.74 (+2.95%)
TSLA   1,527.24 (+11.12%)
GE   6.63 (-1.49%)
MU   48.33 (+1.19%)
AMD   82.24 (+6.97%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.92 (-1.00%)
GILD   68.86 (+1.12%)
NFLX   479.79 (+2.75%)
DIS   131.35 (+0.66%)
BAC   26.56 (-1.34%)
BA   173.96 (-3.43%)
S&P 500   3,383.92 (+1.51%)
DOW   27,962.16 (+0.99%)
QQQ   272.20 (+2.64%)
AAPL   449.76 (+2.80%)
MSFT   208.91 (+2.72%)
FB   260.71 (+1.79%)
GOOGL   1,505.20 (+1.67%)
AMZN   3,155.67 (+2.43%)
NVDA   454.73 (+4.78%)
CGC   17.40 (+2.65%)
BABA   255.74 (+2.95%)
TSLA   1,527.24 (+11.12%)
GE   6.63 (-1.49%)
MU   48.33 (+1.19%)
AMD   82.24 (+6.97%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.92 (-1.00%)
GILD   68.86 (+1.12%)
NFLX   479.79 (+2.75%)
DIS   131.35 (+0.66%)
BAC   26.56 (-1.34%)
BA   173.96 (-3.43%)
Log in

NASDAQ:CYRXCryoPort Stock Price, Forecast & News

$31.35
-1.18 (-3.63 %)
(As of 08/12/2020 01:56 PM ET)
Add
Compare
Today's Range
$31.25
Now: $31.35
$32.94
50-Day Range
$27.61
MA: $32.58
$35.87
52-Week Range
$12.40
Now: $31.35
$36.78
Volume18,222 shs
Average Volume544,187 shs
Market Capitalization$1.19 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.92
CryoPort, Inc. engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers. It offers personalized medicine, immunotherapies, cellular therapies, CAR T-cell therapies, stem cell therapies, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, bio-pharmaceuticals, infectious substances, and other commodities that require continuous exposure to certain ranges of precision-controlled temperatures. The company was founded on May 25, 1990 and is headquartered in Irvine, CA.
Read More
CryoPort logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.15 out of 5 stars


Industry, Sector and Symbol

Industry Freight transportation arrangement
Sub-IndustryN/A
Current SymbolNASDAQ:CYRX
CUSIPN/A
Phone949-470-2300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$33.94 million
Book Value$3.52 per share

Profitability

Net Income$-18,330,000.00

Miscellaneous

EmployeesN/A
Market Cap$1.19 billion
Next Earnings Date11/5/2020 (Estimated)
OptionableOptionable
$31.35
-1.18 (-3.63 %)
(As of 08/12/2020 01:56 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CYRX News and Ratings via Email

Sign-up to receive the latest news and ratings for CYRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CryoPort (NASDAQ:CYRX) Frequently Asked Questions

How has CryoPort's stock been impacted by COVID-19 (Coronavirus)?

CryoPort's stock was trading at $16.62 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CYRX shares have increased by 90.3% and is now trading at $31.63.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of CryoPort?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CryoPort in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for CryoPort
.

When is CryoPort's next earnings date?

CryoPort is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for CryoPort
.

How were CryoPort's earnings last quarter?

CryoPort Inc (NASDAQ:CYRX) issued its quarterly earnings results on Thursday, August, 6th. The consumer goods maker reported ($0.15) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.11) by $0.04. The consumer goods maker had revenue of $9.39 million for the quarter, compared to the consensus estimate of $8.93 million. CryoPort had a negative return on equity of 19.09% and a negative net margin of 60.97%. CryoPort's revenue was up 11.0% on a year-over-year basis. During the same period last year, the business posted ($0.08) earnings per share.
View CryoPort's earnings history
.

What price target have analysts set for CYRX?

5 analysts have issued 12 month target prices for CryoPort's shares. Their forecasts range from $21.00 to $40.00. On average, they expect CryoPort's stock price to reach $29.67 in the next twelve months. This suggests that the stock has a possible downside of 6.2%.
View analysts' price targets for CryoPort
.

Has CryoPort been receiving favorable news coverage?

Media coverage about CYRX stock has trended negative this week, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. CryoPort earned a news impact score of -2.2 on InfoTrie's scale. They also gave media coverage about the consumer goods maker a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term.
View the latest news about CryoPort
.

Are investors shorting CryoPort?

CryoPort saw a increase in short interest in January. As of January 15th, there was short interest totaling 8,800,000 shares, an increase of 14.0% from the December 31st total of 7,720,000 shares. Based on an average trading volume of 422,300 shares, the short-interest ratio is presently 20.8 days.
View CryoPort's Short Interest
.

Who are some of CryoPort's key competitors?

What other stocks do shareholders of CryoPort own?

Who are CryoPort's key executives?

CryoPort's management team includes the following people:
  • Jerrell W. Shelton, Chairman, President & Chief Executive Officer
  • Phil Wilson, SVP-Global Operations & Supply Chain
  • Robert S. Stefanovich, Chief Financial Officer, Secretary & Treasurer
  • Bret Bollinger, Chief Technology Officer
  • Mark W. Sawicki, Chief Commercial Officer

What is CryoPort's stock symbol?

CryoPort trades on the NASDAQ under the ticker symbol "CYRX."

Who are CryoPort's major shareholders?

CryoPort's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (2.68%), TimesSquare Capital Management LLC (1.99%), GW&K Investment Management LLC (1.79%), Granite Investment Partners LLC (0.99%), Columbus Circle Investors (0.78%) and Taylor Wealth Management Partners (0.63%). Company insiders that own CryoPort stock include Jerrell Shelton, Richard J Berman and Robert Stefanovich.
View institutional ownership trends for CryoPort
.

Which institutional investors are selling CryoPort stock?

CYRX stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., TimesSquare Capital Management LLC, Creative Planning, Essex Investment Management Co. LLC, Taylor Wealth Management Partners, Penbrook Management LLC, Genesee Capital Advisors LLC, and Columbus Circle Investors. Company insiders that have sold CryoPort company stock in the last year include Richard J Berman, and Robert Stefanovich.
View insider buying and selling activity for CryoPort
.

Which institutional investors are buying CryoPort stock?

CYRX stock was acquired by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC, SG Americas Securities LLC, Great Lakes Advisors LLC, Bullseye Asset Management LLC, Braun Stacey Associates Inc., New York State Common Retirement Fund, State Board of Administration of Florida Retirement System, and Swiss National Bank.
View insider buying and selling activity for CryoPort
.

How do I buy shares of CryoPort?

Shares of CYRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CryoPort's stock price today?

One share of CYRX stock can currently be purchased for approximately $31.63.

How big of a company is CryoPort?

CryoPort has a market capitalization of $1.21 billion and generates $33.94 million in revenue each year. The consumer goods maker earns $-18,330,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

What is CryoPort's official website?

The official website for CryoPort is www.cryoport.com.

How can I contact CryoPort?

CryoPort's mailing address is 112 Westwood Place Suite 350, Brentwood TN, 37027. The consumer goods maker can be reached via phone at 949-470-2300 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.